Discover Great Companies Discover Great Clients
Popularity  13.7万   |   Followers  323   |   Likes  44   |   Feedback  181 Claim this company

Caring for life, promoting health

No.144 Huangpu District Popularity Ranking Shanghai No.3 Ning Adhesives No.4 Chemistry APIs No.4 Pharmacy No.6 Pharmaceutical Distribution No.6 Antibiotics No.6 Chinese Patent Medicines No.9 Zhong Pharmaceuticals No.9 Pharmaceutical Commercial No.9 Health Products No.10 Pharmaceutical Retail No.10 Generic Drugs No.11 Kang Ti Yao 总部企业 驰名商标 企业技术中心 国家科技进步奖 副会长单位 国家知识产权优势企业 GMP认证 六西格玛
More

Company Overview

  • Nature: Listed Company Size: Over 10,000 employee Founded: 32年
  • Industry: Pharmaceuticals/Biotechnology 、 Wholesale/Retail
  • Full name: Shanghai Pharmaceuticals Holding Co., Ltd.。

Development Stage

  • Stage: IPO上市, 主板, 上交所。
  • Ranking: Ranked #3 in Shanghai Ning Adhesives Company by popularity Ranked #4 in Shanghai Chemistry APIs Company by popularity Ranked #4 in Shanghai Pharmacy Company by popularity Ranked #6 in Shanghai Pharmaceutical Distribution Company by popularity
  • Honors: 2026中国500强 2025中国制造业500强 总部企业 驰名商标 According to algorithm
  • News: 2026-06-12:上海医药:罗沙司他胶囊获国家药监局批准生产。
  • Salary: 65.2% of positions earn 10-20K, In 2026 vs last yeardecreased by 51%.。Master's salary: ¥25.0K.
  • Recruiting: In 2026 vs 2025decreased by 4%. Demand for highly educated talent: Master's: 1.
  • Requirement: Education: 本科 leads with 64%. Experience: 不限 leads with 44%.
  • Region: Distributed across 1 regions, 上海: 56%, 北京: 8%, 本溪: 8%, 南京: 4%.

About the Company

[Summary] Caring for life, promoting health

Shanghai Pharmaceuticals Holding Co., Ltd. (hereinafter referred to as "Shanghai Pharma" or "the Company"), as a core enterprise of Shanghai Industrial (Group) Co., Ltd., is a large pharmaceutical industry group listed on both the Hong Kong and Shanghai stock exchanges (Hong Kong Stock Exchange stock code: 02607; Shanghai Stock Exchange stock code: 601607). The company's main business covers pharmaceutical manufacturing and distribution. In 2024, its operating revenue reached RMB 275.251 billion, ranking among the Fortune Global 500, and in 2025 it rose to 407th place, setting a new record. Its overall strength ranks among the top three pharmaceutical companies in China, and it has been included in the SSE 180 Index, CSI 300 Index, and MSCI China Index.

The company advocates the core corporate values of "Innovation, Integrity, Cooperation, Inclusiveness, and Responsibility," and is committed to persistently improving the quality of people's healthy lives, striving to become a respected, reputable leading brand drug manufacturer and health service provider.

I. Pharmaceutical Manufacturing

Shanghai Pharma adheres to innovative development, continuously increasing R&D investment and accelerating innovation transformation. In 2024, the company's total R&D investment reached RMB 2.818 billion, accounting for 11.88% of industrial sales revenue, of which R&D expenses were RMB 2.394 billion, a year-on-year increase of 8.64%.

In 2024, the company's innovative drug pipeline achieved breakthrough progress, with three indications of I001 in the middle-to-late stages of clinical trials. Among them, the NDA application for the hypertension indication was accepted by the CDE in April 2024. The B001 injection, used for treating neuromyelitis optica spectrum disorder (NMOSD), formally entered key clinical research in 2024. The B007 injection initiated studies on three indications in 2024: membranous nephropathy, myasthenia gravis, and pemphigus. As of the end of 2024, there were 54 new drug pipeline projects whose clinical trial applications had been accepted or had entered subsequent clinical trial stages, including 40 innovative drugs (including one in Phase II clinical trials in the United States) and 14 improved new drugs. Among the innovative drug pipeline, one has been submitted for marketing application, and five are in Phase III clinical trials.

The company's manufacturing covers chemical and biological drugs, modern Chinese medicine and health products, and medical devices, focusing on disease areas such as immunology, neuropsychiatry, oncology, cardiovascular, gastrointestinal and metabolic diseases, and anti-infection. The company has pharmaceutical production bases in 12 provinces and cities in China and overseas, producing about 800 drug specifications and more than 30 dosage forms year-round. In 2024, the company achieved sales of over 100 million yuan for 44 industrial products, of which two products exceeded 1 billion yuan. Multiple drugs have passed quality certifications from the WHO, FDA, EU, and other regulatory bodies and are sold in overseas markets. Under the guidance of the group's overall strategy, the manufacturing segment adheres to the basic principles of quality first, optimal cost, green development, and intelligent manufacturing, driven by system capabilities, aiming for excellent operations and intelligent manufacturing, and carrying out all-round transformation and upgrading of the entire value chain of pharmaceutical manufacturing.

II. Pharmaceutical Distribution

Shanghai Pharma is the second-largest national pharmaceutical distribution enterprise in China and a leading import drug service platform. Its distribution network covers 31 provinces, municipalities, and autonomous regions nationwide, of which it directly covers 25 provinces, municipalities, and autonomous regions through its subsidiary companies. It covers more than 32,000 medical institutions of various types, with its retail network spanning 16 provinces and cities nationwide, with a total of over 2,000 retail pharmacies.

The company has established strategic cooperative relationships with major domestic and international drug manufacturers and continuously promotes service innovation. By providing integrated supply chain services and innovative service solutions such as modern logistics, information services, financial services, and omni-channel integrated marketing services, the company leads industry value innovation and gradually transforms into a "technology-based health service enterprise." The company actively promotes the upgrade of the domestic pharmaceutical and health product supply chain, using technological and information technology, leveraging its platform advantages, accelerating resource collaboration, and continuously expanding new services, new varieties, and new markets with new mechanisms.

In the field of "Internet+" enabling innovative services, the company actively incubates "Internet+" pharmaceutical business technology platforms. Shanghai Pharma Cloud Health deeply integrates "online + offline" to comprehensively develop the Yiyao ecosystem, providing valuable and accessible sales and service networks for the flourishing development of innovative drugs. Medlink Health is committed to deeply integrating the insurance and medical fields, connecting the "Internet + medical + pharmaceutical + insurance" ecological closed loop, providing professional supporting services for China's inclusive insurance projects and serving the construction of China's multi-level medical security system.

Expand
Information is aggregated from the web and may not be exact. For reference only.
Information incorrect? Claim this company to edit

Shanghai Pharma Financing History (1 rounds)

Manage
IPO上市
Capital Market Favor
Latest Financing Round
  • Date: ?
  • Market: 主板
  • Deal: 上交所

Shanghai Pharma How Fast Is Hiring Growing? (14 open positions)

Manage
?
Growth Rate
2026 vs 2025
  • 2025: Down 35%
  • 2024: Down 53%
  • 2023: Up 13%
  • 2022: Down 67%
Shanghai Pharma Year-by-Year Hiring:
* Hiring was generally low during 2020-2022 due to the pandemic
Shanghai Pharma Campus Recruitment & Advanced Degree Talent Demand
Master's 1
Note: How fast is hiring at Shanghai Pharmaceuticals Holding Co., Ltd. growing? Shanghai Pharma2026: 23 openings (down 4%), 2025: 24 openings (down 35%), 2024: 37 openings (down 53%), 2023: 79 openings (up 13%), 2022: 70 openings (down 67%), 2021: 214 openings. A rising curve may indicate expansion; a falling curve may indicate slower growth or good retention. Based on publicly available data, for reference only.

Shanghai Pharma Master's Degree Job Demand Analysis

(More)
?
Growth Rate
2026 vs 2025
  • 2025: Up 40%
  • 2024: Down 80%
  • 2023: Up 14%
  • 2022: Down 35%
Shanghai Pharma Master's Hiring by Year:
* Hiring was generally low during 2020-2022 due to the pandemic
How fast is master's hiring at Shanghai Pharmaceuticals Holding Co., Ltd. growing? Shanghai PharmaMaster's recruitment over the years: 2025: 7 openings (up 40%), 2024: 5 openings (down 80%), 2023: 25 openings (up 14%), 2022: 22 openings (down 35%), 2021: 34 openings.

Shanghai Pharma Doctoral Degree Job Demand Analysis

(More)
N/A
Growth Rate
Shanghai Pharma Doctoral Hiring by Year: 2024 — 10 fewer jobs than 2023
* Hiring was generally low during 2020-2022 due to the pandemic
How fast is doctoral hiring at Shanghai Pharmaceuticals Holding Co., Ltd. growing? Shanghai PharmaDoctorate recruitment over the years: 2024: 1 openings (down 80%), 2023: 11 openings (up 14%), 2022: 4 openings (down 35%), 2021: 13 openings.

Shanghai Pharma — What Are the Salaries Like? (23 records)

Manage
Shanghai Pharma Salary Overview
salary range: 4.5K - 50K, 65.2% of roles pay ¥10-20K
Note: salary statistics are based on 23 salary records from the past year and depend on the job sample. For reference only.
How is the salary at Shanghai Pharmaceuticals Holding Co., Ltd.?Shanghai Pharma65.2% of positions earn 10-20K, Undergraduate salary: ¥。Shanghai salary ranking: #4148,销售类 average salary ¥12.0K。 Note: Based on analysis of job postings, does not represent current on-the-job positions; system stability may affect objectivity. For reference only.Data inaccurate? Let us know

Salaries for hot jobs of Shanghai Pharma

(More)
Are salaries high at Shanghai Pharmaceuticals Holding Co., Ltd.? We provide: Researcher, Information, Senior Manager, Pharmaceutical Sales Representative, Auditor, Product Development Specialist, Product Manager, Analyst, Vice President, 合规, Monetization Manager, Purification Engineer, 药理毒理研究, Procurement, Project Management. Click to view detailed salary analysis by job.

Shanghai Pharma — Fortune 500? (More)

Yes, ranked in 中国500强:

  • NO.96 2026中国500强 >
  • NO.98 2025中国500强 >
  • NO.106 2024中国500强 >

Yes, ranked in 中国制造业500强:

  • NO.36 2025中国制造业500强 >
  • NO.43 2024中国制造业500强 >
  • NO.50 2023中国制造业500强 >

Job Category

  • 销售类
    28% of total 28%
  • 其他(研发和技术类)
    24% of total 24%
  • 生物/制药/化工/环保类
    24% of total 24%
  • 科研类
    24% of total 24%

Education

  • 本科
    64% of total 64%
  • 硕士
    20% of total 20%
  • 大专
    16% of total 16%

Experience

  • 不限
    44% of total 44%
  • 1-3年
    32% of total 32%
  • 5-10年
    24% of total 24%
View Detailed Analysis

What does Shanghai Pharmaceuticals Holding Co., Ltd. require? Who is Shanghai Pharma hiring? Shanghai Pharma recruitment: 销售类占比最多占28%,其次是其他(研发和技术类)占24%. What education can get in at Shanghai Pharma? 本科占比最多占64%,其次是硕士占20%. High education required at Shanghai Pharma? 硕士占20%. Work experience required at Shanghai Pharma? 不限占比最多占44%,其次是1-3年占32%. Where are the job locations at Shanghai Pharma? 上海占比最多占56%,其次是北京占8%. Based on job postings from the past year, for reference only.

Business Registration

Provided by

Operating Status: 开业
Registered Capital: 370,278.8059万(元)
Legal Representative: 杨秋华
Date Established:
Credit Code: 9131000013358488X7
Registered Address: 中国(上海)自由贸易试验区张江路92号

Partners & Suppliers

上海医药为那瑞医药提供区域分销服务,将其产品引入华东市场。 Source
供应商 医药商业
提供药品分装、仓库保管等劳务派遣 Source
供应商 医药
上海医药作为区域分销商,采购加蓓康(广州)医药控股有限公司的药品并在华东地区销售。 Source
供应商 渠道分销
上海医药为淮南健坤的部分药品提供分销 Source
供应商 医药商业分销
四川百利药业通过上海医药分销药品 Source
供应商 医药商业流通

People who follow Shanghai Pharma also follow

Shanghai Pharma Competitors (Similar Companies)

“Promoting human health”
“To develop high-quality biologics that are accessible and affordable f”
“Research, development, and production of anti-tumor and surgical medic”
“Continuously innovating to bring patients medicines that significantly”
“Technological innovation and commercial application of pharmaceutical ”
“A national modern pharmaceutical supply chain service enterprise with ”
“One of Roche's five global drug development centers”
“Developing innovative drugs to improve human health”
“The first domestic pharmaceutical distribution enterprise with busines”
“Bring the digital world to every person, home, and organization, to bu”
“New energy vehicle manufacturer”
“A leading open-access capability and technology platform company for p”
“Adhering to the corporate culture of science and excellence, committed”
飞行器 飞机 水域救援 大数据
“Helping our customers make the world healthier, cleaner, and safer”

Discover Great Companies, Discover Great Clients

上海公司名录 上海“Huangpu District”公司名录 上海“抗生素”公司名录 上海“中成药”公司名录 上海“临床医学”公司名录 上海“化学制药”公司名录 上海“医药流通”公司名录 附近的公司

Report

*Reason:

Radical political or ideological topics
Advertising or spam
Pornographic or vulgar content
Obscene language or personal attacks
Other

Congratulations, submitted successfully!

Your edit is under review. You will be notified by email within 1 business day.

Submission failed.

Followed successfully. We'll notify you of any company updates.

Help others learn about this company, add my impression of this company»

Log in with the following accounts to save your follows

Followed successfully, we'll notify you of any company updates